AHF dismayed at FDA decision to expedite review for expanded use of Gileads AIDS drug.

‘The FDA is not thinking about seeing or hearing anything that may contradict its settled program,’ commented Weinstein.. AHF dismayed at FDA decision to expedite review for expanded use of Gilead’s AIDS drug, Truvada AIDS Healthcare Basis , the country’s largest HIV/AIDS non-profit medical company, today expressed its disappointment and dismay in the Food and Medication Administration’s decision to grant an expedited review for Gilead Sciences’ application for expanded usage of its blockbuster AIDS drug, Truvada, as a means of preventing HIV infections in noninfected people. Most alarmingly, the chance continues to be after people stop taking the drug even.‘Recently, we’ve devoted a great deal of work to developing highly delicate and selective proteomics equipment for research, and we’re delighted to see them being used to such great effect for this vital function.’ The initial collaboration, announced in October 2009, includes using Agilent triple quadrupole and quadrupole time-of-flight liquid chromatography/mass spectrometry systems; nanoflow HPLC-Chip/MS systems; and protein analysis software program at ISB in Seattle and ETH Zurich, to create a map of most human proteins.